By Tiffany Williams –
HARTFORD, Conn. — Attorney General William Tong announced Friday approximately $720 million in new multistate settlements with eight pharmaceutical manufacturers accused of exacerbating the nationwide opioid crisis through the production and distribution of addictive prescription painkillers. Connecticut could receive up to $8.4 million from the agreements, which now move into a sign-on period for local governments and municipalities.
The funds will support Connecticut’s ongoing efforts to address the opioid epidemic through treatment, prevention, harm reduction, and recovery services. Tong noted that these settlements build upon the $600 million already secured for Connecticut as part of broader multistate efforts, of which over $110 million has already been allocated toward statewide initiatives.
Among the programs funded: naloxone distribution, mobile treatment vans, and a $58 million “Housing as Recovery” investment to provide long-term support for those in recovery.
As part of the new agreement, Mylan (now part of Viatris) will pay $284.4 million over nine years, Hikma will pay $95.8 million over one to four years, and Amneal will pay $71.8 million over ten years. Apotex will contribute $63.7 million in a single-year payment, while Indivior has agreed to pay $38 million over four years. Sun Pharma will pay $31 million over one to four years, and both Alvogen and Zydus will each pay $18.7 million and $14.9 million respectively, also in single-year payments.
Beyond financial payments, several companies will also provide free pharmaceutical products or cash equivalents and implement new monitoring systems for suspicious orders. Seven companies—excluding Indivior—are prohibited from marketing or promoting opioid products, and from producing pills with more than 40 mg of oxycodone per dose. Indivior, which manufactures medication for opioid use disorder, has agreed to halt opioid production for the next 10 years.
Connecticut has played a leading role in securing over $50 billion nationwide in opioid-related settlements. The state’s Opioid Settlement Advisory Committee, which includes medical professionals, individuals with lived experience, and municipal leaders, oversees the allocation and transparency of these critical resources.